COMPANY

AMO Pharma

HQ: Essex Fells, NJ (US office) source · amo-pharma.com ↗

Keywords: rare disease Phelan-McDermid syndrome myotonic dystrophy type 1 Rett syndrome Congenital Myotonic Dystrophy Myotonic Dystrophy 1 Tideglusib

Location: Essex Fells, NJ (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Aug 23, 2021 Trial start Phase 2/Phase 3: Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy source ↗
Mar 3, 2021 Trial start Phase 2/Phase 3: Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy source ↗
Jul 20, 2016 Trial start Phase 2: Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy source ↗

Dec 31, 2026 (ESTIMATED) · Phase 2/Phase 3 · Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy · NCT05004129

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT03692312	Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy	Phase 2/Phase 3	Completed	Mar 3, 2021	Apr 4, 2023 (actual)
NCT02858908	Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy	Phase 2	Completed	Jul 20, 2016	2018-01 (actual)
NCT07119775	Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy	Not listed	Available	Not listed	Not listed
NCT05004129	Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy	Phase 2/Phase 3	Recruiting	Aug 23, 2021	Dec 31, 2026 (estimated)